Key takeaways
- MUSE cells (Multilineage-differentiating Stress-Enduring cells) are a naturally occurring, pluripotent-like subset of stem cells first described in adult human mesenchymal populations in 2010.
- In laboratory and animal studies they have shown the ability to home to damaged tissue, differentiate, and reduce injury markers without forming tumors.
- The strongest evidence so far is preclinical: animal models of heart attack and stroke. Large human clinical trials are early or ongoing.
- MUSE cell therapy remains investigational and is not an approved standard treatment in most jurisdictions.
- Any consideration of stem cell approaches should happen under qualified physician oversight, with realistic expectations grounded in the current evidence.
What are MUSE cells?
MUSE stands for Multilineage-differentiating Stress-Enduring cells. They are a distinct population of stem cells that occur naturally in the body, first characterized in adult human mesenchymal populations and reported in PNAS in 2010. Unlike most stem cells used in research, MUSE cells are identified by a surface marker called SSEA-3 and are described as pluripotent-like, meaning they show the capacity to give rise to cell types from multiple lineages.
One feature has drawn particular attention: in that foundational work, MUSE cells were stress-tolerant and non-tumorigenic in the models studied. The absence of tumor formation is notable because it has historically been a safety concern with more primitive pluripotent stem cells. It is worth being clear that these are early laboratory characterizations, not clinical guarantees.
How they are thought to work
A 2018 review in Advances in Experimental Medicine and Biology framed MUSE cells as endogenous reparative stem cells, meaning the body appears to hold a reservoir of them that can be mobilized in response to injury. According to that work, MUSE cells can mobilize from the bone marrow and travel toward damaged tissue.
The proposed homing mechanism centers on a signaling pathway known as the S1P-S1PR2 axis, which is thought to guide the cells toward sites of injury. Once there, research suggests they may contribute both by differentiating into local cell types and through paracrine effects, releasing signaling factors that influence the surrounding tissue. These are mechanistic findings drawn largely from laboratory and animal research rather than from confirmed human outcomes.
What the research shows
The current evidence base is dominated by preclinical and mechanism studies. In a 2018 study published in Circulation Research, the S1P-S1PR2 homing axis was examined in a rabbit model of acute myocardial infarction (heart attack), where MUSE cell treatment was associated with reduced infarct size and improved ejection fraction. These are encouraging animal results, but they are animal results.
In neurological research, a 2017 study in Stroke reported that human MUSE cells could engraft and differentiate into neurons in a subacute stroke model, reconstructing elements of neuronal circuitry, again without tumor formation in the model. A separate 2016 mechanistic paper in the Journal of Stroke and Cerebrovascular Diseases documented endogenous mobilization of MUSE cells in ischemic stroke, including observations in humans. Importantly, the authors of that work noted that clinical trials were ongoing or at an early stage. Taken together, the picture is one of consistent and promising signals in animals and mechanism studies, with human clinical validation still limited and unfolding.
What MUSE cells are being explored for
Based on the supplied research, MUSE cells are primarily being investigated in the context of tissue repair after acute injury, most prominently following heart attack and stroke, where the ability to home to damaged tissue and support repair is the central question. The non-tumorigenic profile observed in these studies is part of why they continue to attract research interest.
It is important to hold this honestly: these areas represent research directions, not established treatments. MUSE cell therapy is investigational, the large human trials that would establish clear benefit are early or in progress, and it is not an approved standard-of-care therapy in most jurisdictions. Anyone reading about MUSE cells should treat the field as emerging rather than settled.
How Strong Craft Regen approaches this
Strong Craft Regen is a coordination and education service, not a clinic and not a substitute for medical advice. We help people understand the current state of regenerative science honestly, and we coordinate care delivered by licensed physicians at Innovita Clinic in Vilnius, Lithuania. With an emerging area like MUSE cells, our role is to keep expectations grounded in what the evidence actually supports and to make sure any decision happens with proper physician oversight.
If you are exploring regenerative options and want to understand what is genuinely supported by research versus what remains experimental, we are glad to talk it through. You can book a call to discuss your situation, and the physicians we coordinate with can assess whether anything is appropriate, safe, and available for you. This article is educational only and is not a treatment recommendation.
The evidence
Selected peer-reviewed references, each verified against PubMed. Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. MUSE Cells is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.